Fredag 6 December | 23:37:04 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-11 07:00 Kvartalsrapport 2025-Q3
2025-08-28 07:00 Kvartalsrapport 2025-Q2
2025-05-22 07:00 Kvartalsrapport 2025-Q1
2025-04-29 N/A Årsstämma
2025-02-27 07:00 Bokslutskommuniké 2024
2024-11-11 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-22 - Kvartalsrapport 2024-Q1
2024-04-25 - X-dag ordinarie utdelning SCOL 0.00 SEK
2024-04-24 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-04-27 - X-dag ordinarie utdelning SCOL 0.00 SEK
2023-04-26 - Årsstämma
2023-02-22 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - Kvartalsrapport 2022-Q1
2022-04-28 - X-dag ordinarie utdelning SCOL 0.00 SEK
2022-04-27 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-11-17 - Extra Bolagsstämma 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning SCOL 0.00 SEK
2021-05-26 - Årsstämma
2021-05-20 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning SCOL 0.00 SEK
2020-05-27 - Årsstämma
2020-05-21 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-21 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-06-11 - Extra Bolagsstämma 2019
2019-05-31 - X-dag ordinarie utdelning SCOL 0.00 SEK
2019-05-29 - Årsstämma
2019-05-27 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018
2018-11-18 - Kvartalsrapport 2018-Q3

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Scandion Oncology är verksamt inom bioteknik. Bolaget är fokuserat inom utveckling av läkemedel för behandling av cancer som innehåller läkemedelsresistenta cellkloner. Bolagets läkemedelskandidat, SCO-101, har i prekliniska studier använts inom olika standardcancerbehandlingar. Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn, Danmark.
2024-07-01 17:30:00

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced that Michel Ducreux, board member since May 2024 is stepping down from his position. Ducreux is also co-chair of the European Society For Medical Oncology Gastrointestinal Congress 2024 and 2025 organization and member of the clinical guidelines committee. He is stepping down due to the scientific society’s guidelines prohibiting such board positions.

Michel Ducreux, MD, PhD, will continue to support Scandion in an advisory role on the company’s advisory board, where his extensive knowledge and expertise can continue to benefit Scandion.

For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com

About this information

The information was submitted for publication, through the agency of the contact persons set out above, on July 1, 2024, at 17.30 CET.

About Scandion Oncology

Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.

Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.

Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.